---
title: "Foghorn Therapeutics to Present New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/282183755.md"
description: "Recent preclinical findings regarding FHD-909 (also known as LY4050784) have shown promising results, indicating the possibility of further development opportunities when used in conjunction with an anti-PD-1 antibody for SMARCA4 (BRG1)-mutant lung cancer. The data suggests that this combination therapy could be effective in targeting this specific type of lung cancer, potentially leading to improved treatment outcomes. This discovery opens up new avenues for research and development in the field of oncology."
datetime: "2026-04-09T11:01:32.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/282183755.md)
  - [en](https://longbridge.com/en/news/282183755.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/282183755.md)
generator: "portal-rs"
---

# Foghorn Therapeutics to Present New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting

Recent preclinical findings regarding FHD-909 (also known as LY4050784) have shown promising results, indicating the possibility of further development opportunities when used in conjunction with an anti-PD-1 antibody for SMARCA4 (BRG1)-mutant lung cancer. The data suggests that this combination therapy could be effective in targeting this specific type of lung cancer, potentially leading to improved treatment outcomes. This discovery opens up new avenues for research and development in the field of oncology.

### Related Stocks

- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [FHTX.US](https://longbridge.com/en/quote/FHTX.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)

## Related News & Research

- [Foghorn Therapeutics Q2 FY26 net loss narrows to $7.2 million; collaboration revenue rises to $16.1 million](https://longbridge.com/en/news/295098647.md)
- [LIVE MARKETS-BofA clients flock to tech stocks](https://longbridge.com/en/news/296383193.md)
- [SBIO: U.S. Programmatic and EMEA drove 49% of Q2 sales, with margins rising to 61% and profitability expected in H2 2026](https://longbridge.com/en/news/296517769.md)
- [Moderna surges on trial win for cancer shot; William Blair upgrades](https://longbridge.com/en/news/296370751.md)
- [Guotai Asset Management sees liquidity boost driving China biotech, innovation drug shares higher](https://longbridge.com/en/news/296448906.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**